HAV⁽²⁾ and HBV⁽²⁾ vaccination should be given to men who have sex with men, patients with underlying liver disease or patients with HIV infection.
HBV⁽²⁾ vaccination should also be given to patients with chronic renal disease including those on hemodialysis.
HAV⁽²⁾ vaccine is given at 0 and 6 months.
HBV⁽²⁾ vaccine is given at 0, 1 and 6 months.
Immunocompromised patients require a double dose of HBV⁽²⁾ vaccine to enhance immunogenicity. Hepatitis B surface antigen titers should be checked after completion of vaccination series and if they are below 10, a repeat vaccine series should be performed.
(1) Live attenuated vaccine
(2) Inactive or component vaccine
(3) Only covered by MSP for certain indications
PPSV‐23: 23 valent pneumococcal polysaccharide vaccine
PCV‐13: 13 valent pneumococcal conjugate vaccine